Sandoz agrees $450 million settlement with 43 states over generic drug pricing

By ··2 min read

Sandoz has agreed to pay about $450 million to resolve antitrust claims brought by 43 US states and territories over alleged price-fixing and market allocation in the generic drug market. The company said the deal contains no admission of wrongdoing and resolves all remaining US government claims against it from the long-running investigation.

Sandoz announced on August 3, 2026, that its US subsidiary Sandoz Inc. and Fougera Pharmaceuticals Inc. have agreed to settle all remaining claims brought by 43 US states and territories in three cases pending in the US District Court for the District of Connecticut. Sandoz Inc. will pay $400 million over seven years beginning in 2027, plus approximately $50 million to states that settled earlier, for a total of roughly $450 million. The settlement is conditional on approval by all of the litigating states and territories.

The state cases grew out of a multi-year investigation by state attorneys general into alleged price-fixing and customer allocation among generic drug manufacturers, in which Sandoz and Fougera were named alongside other generic makers. The conduct at issue dates from the period when Sandoz was part of Novartis, which spun off the generics business as a separately listed company in October 2023. Separately, Sandoz agreed to pay $28.5 million to a putative class of indirect reseller plaintiffs — generally retail pharmacies, clinics and hospitals — in the multidistrict litigation in the Eastern District of Pennsylvania, subject to court approval.

Sandoz said neither settlement contains an admission of wrongdoing and that the payments do not affect its full-year 2026 guidance. The company said it continues to defend itself against remaining claims from individual opt-out plaintiffs.

The deal is a significant marker in the generic drug price-fixing saga. Sandoz previously resolved federal exposure through a deferred prosecution agreement with the DOJ Antitrust Division in 2020 and a False Claims Act settlement in 2021. With this agreement, the company says it will have resolved all pending class actions in the US generic antitrust litigation and all claims filed by any US federal or state government.

The states' settlement still requires sign-off from every participating jurisdiction, and the indirect reseller settlement requires court approval. Payments are scheduled to begin in 2027. Opt-out claims against Sandoz remain active.

Cite this report

The Precedent. "Sandoz agrees $450 million settlement with 43 states over generic drug pricing." September 9, 2026. https://theprecedent.org/article/sandoz-agrees-450-million-settlement-with-43-states-over-generic-drug-pricing